NCT06250244 2024-12-11
177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
Clinical Trials
14 trialsNCT05558956 2023-07-27
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
BAMF Health
Phase EARLY_PHASE1 Unknown
NCT05955209 2023-07-21
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05823402 2023-05-03
SPECTacular
BAMF Health
Phase NA Unknown
NCT05533203 2023-01-23
Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shanghai Humantech Biotechnology Co. Ltd
Phase 1 Unknown
NCT03692663 2022-08-01
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03780075 2022-05-12
Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1 Unknown
NCT05327621 2022-04-14
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04853498 2021-11-24
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04586543 2020-10-14
Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
University of Pecs
Phase 2 Unknown
NCT04225910 2020-01-13
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Unknown
NCT03403595 2018-01-18
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1 Unknown
NCT02044354 2017-08-08
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Unknown
NCT03085966 2017-03-21
Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC
Shanghai AbelZeta Ltd.
Phase 1/2 Unknown